Pathogenic somatic mutations in the mechanistic target of rapamycin (mTOR) pathway genes can cause focal cortical dysplasia (FCD) spectrum disorders that are associated with pharmaco-resistant epilepsy, such as FCD Type 2, hemimegalencephaly (HME) and tuberous sclerosis complex (TSC). The gene discussed is MTOR; the disease is Focal cortical dysplasia.